| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
Aripiprazole (formerly OPC-14597; OPC 14597; OPC14597; trade name Abilify) is an approved atypical antipsychotic drug that acts as a high-affinity partial agonist of 5-HT receptor. It is a powerful partial agonist at dopamine D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing the dopamine-serotonin system. Furthermore, aripiprazole has been reported to bind with the antagonist [3H]spiperone and the agonist [125I]7-OH-PIPAT at 0.70±0.22nM and 0.34±0.02nM, respectively.
| Targets |
5-HT1A Receptor ( Ki = 4.2 nM ); 5-HT2A Receptor; 5-HT2B Receptor; 5-HT2C Receptor; D2 Receptor; D3 Receptor; D4 Receptor
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C23H27CL2N3O2
|
|
|---|---|---|
| Molecular Weight |
448.39
|
|
| Exact Mass |
447.15
|
|
| Elemental Analysis |
C, 61.61; H, 6.07; Cl, 15.81; N, 9.37; O, 7.14
|
|
| CAS # |
129722-12-9
|
|
| Related CAS # |
Aripiprazole-d8; 1089115-06-9; Aripiprazole (1,1,2,2,3,3,4,4-d8); 1089115-04-7; Aripiprazole monohydrate; 851220-85-4; 1259305-26-4 (cavoxil)
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
|
|
| InChi Key |
CEUORZQYGODEFX-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
|
|
| Chemical Name |
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 2.5 mg/mL (5.58 mM) in 10% DMF 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Solubility in Formulation 4: 2.5 mg/mL (5.58 mM) in 10% DMF 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2302 mL | 11.1510 mL | 22.3020 mL | |
| 5 mM | 0.4460 mL | 2.2302 mL | 4.4604 mL | |
| 10 mM | 0.2230 mL | 1.1151 mL | 2.2302 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04812379 | Active Recruiting |
Drug: Aripiprazole | Bipolar Disorder I | Otsuka Pharmaceutical Co., Ltd. | April 7, 2021 | N/A |
| NCT03522168 | Active Recruiting |
Drug: Risperidone Drug: Aripiprazole |
Weight, Body | Duke University | January 10, 2019 | N/A |
| NCT05531591 | Active Recruiting |
Drug: Aripiprazole Augmentation Drug: Switch to bupropion |
Depression Dementia |
Centre for Addiction and Mental Health |
August 1, 2019 | Phase 4 |
| NCT05322031 | Recruiting | Drug: Aripiprazole | Schizophrenia Cognition Disorder |
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
January 1, 2022 | Phase 4 |
| NCT05545891 | Not yet recruiting | Drug: Placebo Drug: Aripiprazole |
Dermatillomania Trichotillomania (Hair-Pulling Disorder) |
University of Chicago | December 2023 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
